Diagnostics

The company reports major clinical trial progress for Duchenne, FA, and CPVT, while its next-gen capsid technology gains widespread industry adoption.

WNBA star Erica Wheeler lost her mom to cervical cancer. Now, she's teaming up with Hologic to tackle a worrying rise in cases and save lives.

Propanc Biopharma is taking a 100-year-old cancer treatment concept into modern human trials, targeting advanced tumors and expanding into fibrosis.

AI promises to slash doctor burnout and paperwork, giving physicians more time with patients while boosting practice profitability. But can it deliver?

Beyond oral care, Colgate-Palmolive is reshaping rural India with initiatives in water conservation, digital literacy, and waste management.

Aptar's 'Beat the Blink' technology, in partnership with Bausch + Lomb, promises to solve the age-old problem of inaccurate eye drop dosing.

Fullscript and ŌURA are integrating biometric data into clinical workflows, promising a new era of personalized medicine. But is healthcare ready for it?

A tech firm is leveraging sound waves to overcome key hurdles in brain-computer interfaces, paving the way for advanced rehabilitation and assistive care.

Avalon GloboCare regains Nasdaq compliance, but its future is being reshaped by a bold AI launch and a transformative merger that questions its identity.

FirmTech is taking its AI-powered sexual wellness wearables worldwide, betting on data to revolutionize men's health. But can it navigate global privacy hurdles?

With $6.5M CAD in new funding, Montréal's AI4Eyes is set to accelerate the global launch of its all-in-one diagnostic and treatment platform.

NYU Langone and tech firm Tempus are launching a new protocol using serial DNA sequencing and AI to create hyper-personalized cancer treatments.

For the 24th straight year, nurses top Gallup's ethics poll, but this enduring trust masks a profession in crisis, battling burnout and staff shortages.

A major new partnership is racing to deploy predictive tech, from blood tests to eye scans, to prevent millions of stillbirths in years, not decades.

Promising new 96-week data shows Vir's therapy could redefine care for severe hepatitis delta, as its oncology pipeline and financial runway also advance.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

Adaptive posted a 55% revenue surge in 2025, fueled by its clonoSEQ cancer test. Now, the firm is charting a clear course to company-wide profitability.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

WindRose and Francisco Partners invest in Avalon, signaling a major shift toward tech-driven management of the multi-billion dollar diagnostic testing market.

Amidst a strategic push for profitability, CytoSorbents advances its DrugSorb-ATR device, aiming to revolutionize safety in cardiac surgery.